Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)

Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00753051

Acronym

TCRS

Enrollment

Registered

2008-09-16

Start date

2008-06-30

Completion date

2012-05-31

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

clozapine-resistant schizophrenics, haloperidol augmenting clozapine, electroconvulsive therapy augmenting clozapine

Brief summary

Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a randomized control trial.

Interventions

DRUGclozapine+haloperidol

clozapine 300-900 mg/d haloperidol 4-60 mg/d

DRUGclozapine,electroconvulsive therapy

clozapine 300-900 mg/d electroconvulsive therapy 4-12 times

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. schizophrenic patients diagnosed with schedules for clinical assessment in neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10 2. Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage 3. Voluntary to participate the research protocol expressed by signing informed consent form

Exclusion criteria

1. Patient does not volunteer himself or herself 2. Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate 3. Patient is deaf, blind , dumb to obstruct good communication

Design outcomes

Primary

Measure	Time frame
PANSS , HAM-D , CGI , AIMS Scores	every 4 weeks for 24 weeks

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026